Dealing With High-Risk AL Amyloidosis Patients: A Single Hematologic Center Experience

Area of Science:

• Hematology
• Oncology
• Internal Medicine

Background:

• AL-amyloidosis is a plasma cell dyscrasia with significant morbidity and mortality.
• High-risk patients often require intensive treatment strategies.
• Bortezomib has emerged as a key agent in managing plasma cell disorders.

Purpose of the Study:

• To evaluate the feasibility and outcomes of Bortezomib-based treatment for high-risk AL-amyloidosis.
• To assess treatment response and survival in this patient cohort.
• To identify predictors of survival in high-risk AL-amyloidosis.

Main Methods:

• Retrospective analysis of 52 high-risk AL-amyloidosis patients.
• First-line treatment with Bortezomib-based chemotherapy.
• Assessment of hematologic response at day 30.
• Survival analysis with a median follow-up of 28.5 months.

Main Results:

• A hematologic response (CR+VGPR) was achieved by 44% of patients, with partial response in 27%.
• Median overall survival was 43 months for responders, 24 months for partial responders, and 11 months for non-responders (P < .001).
• Early hematologic response (day 30), NYHA class I-II, and NTproBNP < 6500 ng/L independently predicted survival.

Conclusions:

• Bortezomib-based therapy is safe and effective for high-risk AL-amyloidosis in a hematology ward setting.
• Early partial hematologic response can predict later organ response and improved survival.
• This approach may allow for subsequent therapies and better long-term outcomes.